Cáncer de Vejiga

Cornelissen SWE, Veenboer PW, Wessels FJ, Meijer RP. Diagnostic Accuracy of Multiparametric MRI for Local Staging of Bladder Cancer: A Systematic Review and Meta-Analysis. Urology. 2020 Nov;145:22-29. doi: 10.1016/j.urology.2020.07.021. Epub 2020 Jul 25. PMID: 32721515. (Ver)

Boström PJ, Jensen JB, Jerlström T, Arum CJ, Gudjonsson S, Ettala O, Syvänen KT. Clinical markers of morbidity, mortality and survival in bladder cancer patients treated with radical cystectomy. A systematic review. Scand J Urol. 2020 Aug;54(4):267-276. doi: 10.1080/21681805.2020.1773527. Epub 2020 Jun 9. PMID: 32516016. (Ver)

Krajewski W, Nowak Ł, Poletajew S, Tukiendorf A, Moschini M, Mari A, Di Trapani E, Xylinas E, Kiełb P, Wełna M, Zdrojowy R. The Impact of Restaging Transurethral Resection of Bladder Tumor on Survival Parameters in T1 Nonmuscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis. J Endourol. 2020 Aug;34(8):795-804. doi: 10.1089/end.2020.0301. Epub 2020 Jun 3. PMID: 32336149. (Ver)

Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. Eur Urol. 2020 Sep;78(3):387-399. doi: 10.1016/j.eururo.2020.02.012. Epub 2020 Mar 4. PMID: 32143924. (Ver)

Bruins HM, Veskimäe E, Hernández V, Neuzillet Y, Cathomas R, Compérat EM, Cowan NC, Gakis G, Espinós EL, Lorch A, Ribal MJ, Rouanne M, Thalmann GN, Yuan Y, der Heijden AGV, Witjes JA. The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. Eur Urol Oncol. 2020 Apr;3(2):131-144. doi: 10.1016/j.euo.2019.11.005. Epub 2019 Dec 19. PMID: 31866215. (Ver)

Russell B, Liedberg F, Khan MS, Nair R, Thurairaja R, Malde S, Kumar P, Bryan RT, Van Hemelrijck M. A Systematic Review and Meta-analysis of Delay in Radical Cystectomy and the Effect on Survival in Bladder Cancer Patients. Eur Urol Oncol. 2020 Apr;3(2):239-249. doi: 10.1016/j.euo.2019.09.008. Epub 2019 Oct 23. PMID: 31668714. (Ver)

Kardoust Parizi M, Enikeev D, Glybochko PV, Seebacher V, Janisch F, Fajkovic H, Chłosta PL, Shariat SF. Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis. World J Urol. 2020 Jun;38(6):1437-1449. doi: 10.1007/s00345-019-02936-y. Epub 2019 Sep 6. PMID: 31493109; PMCID: PMC7245585. (Ver)

EAU Guidelines. Non-muscle-invasive Bladder Cancer (Ver)

EAU Guidelines. Muscle-invasive and Metastatic Bladder Cancer (Ver)

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Mar;18(3):329-354. doi: 10.6004/jnccn.2020.0011. PMID: 32135513. (Ver)

Chang SS, Boorjian SA, Chou R et al: Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016; 196: 1021. (Ver)

Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A; ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25 Suppl 3:iii40-8. doi: 10.1093/annonc/mdu223. Epub 2014 Aug 5. PMID: 25096609. (Ver)

Cáncer de próstata

Ku SY, Gleave ME, Beltran H. Towards precision oncology in advanced prostate cancer. Nat Rev Urol. 2019 Nov;16(11):645-654. doi: 10.1038/s41585-019-0237-8. Epub 2019 Oct 7. PMID: 31591549; PMCID: PMC6858516. (Ver)

Malik A, Srinivasan S, Batra J. A New Era of Prostate Cancer Precision Medicine. Front Oncol. 2019 Nov 26;9:1263. doi: 10.3389/fonc.2019.01263. PMID: 31850193; PMCID: PMC6901987. (Ver)

Tsao T, Beretov J, Ni J, Bai X, Bucci J, Graham P, Li Y. Cancer stem cells in prostate cancer radioresistance. Cancer Lett. 2019 Nov 28;465:94-104. doi: 10.1016/j.canlet.2019.08.020. Epub 2019 Sep 4. PMID: 31493443. (Ver)

De Vincentis G, Gerritsen W, Gschwend JE, Hacker M, Lewington V, O’Sullivan JM, Oya M, Pacilio M, Parker C, Shore N, Sartor O; Targeted Alpha Therapy Prostate Working Group. Advances in targeted alpha therapy for prostate cancer. Ann Oncol. 2019 Nov 1;30(11):1728-1739. doi: 10.1093/annonc/mdz270. PMID: 31418764; PMCID: PMC6927314. (Ver)

Stabile A, Giganti F, Rosenkrantz AB, Taneja SS, Villeirs G, Gill IS, Allen C, Emberton M, Moore CM, Kasivisvanathan V. Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nat Rev Urol. 2020 Jan;17(1):41-61. doi: 10.1038/s41585-019-0212-4. Epub 2019 Jul 17. PMID: 31316185. (Ver)

Ali A, Parker CC, Clarke NW. Prostate radiotherapy in newly diagnosed metastatic prostate cancer. Curr Opin Urol. 2019 Nov;29(6):620-628. doi: 10.1097/MOU.0000000000000675. PMID: 31584887. (Ver)

Jenjitranant P, Touijer KA. Role of surgery in oligometastatic prostate cancer. Prostate Int. 2019 Dec;7(4):125-130. doi: 10.1016/j.prnil.2019.10.001. Epub 2019 Dec 3. PMID: 31970136; PMCID: PMC6962728. (Ver)

Walz S, Maas M, Stenzl A, Todenhöfer T. Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review. World J Mens Health. 2020 Apr;38(2):151-163. doi: 10.5534/wjmh.190044. Epub 2019 May 2. PMID: 31081297; PMCID: PMC7076314. (Ver)

Ranasinghe WKB, Reichard CA, Bathala T, Chapin BF. Management of cT4 Prostate Cancer. Eur Urol Focus. 2020 Mar 15;6(2):221-226. doi: 10.1016/j.euf.2019.06.012. Epub 2019 Jun 30. PMID: 31266732. (Ver)

Moris L, Cumberbatch MG, Van den Broeck T, Gandaglia G, Fossati N, Kelly B, Pal R, Briers E, Cornford P, De Santis M, Fanti S, Gillessen S, Grummet JP, Henry AM, Lam TBL, Lardas M, Liew M, Mason MD, Omar MI, Rouvière O, Schoots IG, Tilki D, van den Bergh RCN, van Der Kwast TH, van Der Poel HG, Willemse PM, Yuan CY, Konety B, Dorff T, Jain S, Mottet N, Wiegel T. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol. 2020 May;77(5):614-627. doi: 10.1016/j.eururo.2020.01.033. Epub 2020 Mar 4. PMID: 32146018. (Ver)

A M El Badri S, Salawu A, Brown JE. Bone Health in Men with Prostate Cancer: Review Article. Curr Osteoporos Rep. 2019 Dec;17(6):527-537. doi: 10.1007/s11914-019-00536-8. PMID: 31760582; PMCID: PMC6944652. (Ver)

Slaoui A, Albisinni S, Aoun F, Assenmacher G, Al Hajj Obeid W, Diamand R, Regragui S, Touzani A, Bakar A, Mesfioui A, Karmouni T, Ameur A, Elkhader K, Koutani A, Ibnattya A, Roumeguere T, Peltier A. A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills? World J Urol. 2019 Nov;37(11):2343-2353. doi: 10.1007/s00345-019-02652-7. Epub 2019 Jan 31. PMID: 30706122. (Ver)

Albisinni S, Aoun F, Diamand R, Al-Hajj Obeid W, Porpiglia F, Roumeguère T, De Nunzio C. Cytoreductive prostatectomy: what is the evidence? A systematic review. Minerva Urol Nefrol. 2019 Feb;71(1):1-8. doi: 10.23736/S0393-2249.18.03319-2. Epub 2018 Dec 14. PMID: 30547907. (Ver)

Bastos DA, Antonarakis ES. Darolutamide For Castration-Resistant Prostate Cancer. Onco Targets Ther. 2019 Oct 23;12:8769-8777. doi: 10.2147/OTT.S197244. PMID: 31695432; PMCID: PMC6816030. (Ver)

Swami U, Agarwal N. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer. Cancer Treat Res Commun. 2020 Aug 12;25:100205. doi: 10.1016/j.ctarc.2020.100205. Epub ahead of print. PMID: 32822968. (Ver)

Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, Schuettfort VM, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, Shariat SF. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int J Clin Oncol. 2020 Sep 14. doi: 10.1007/s10147-020-01777-9. Epub ahead of print. PMID: 32924096. (Ver)

Liu Z, Zhang T, Ma Z, Zheng S, Chen J, Wu Z, Zheng X, Li X, Liu Z. Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis. Am J Clin Oncol. 2020 Apr;43(4):288-297. doi: 10.1097/COC.0000000000000660. PMID: 31972568. (Ver)

Rosiello G, Bandini M, Briganti A. Salvage pelvic lymph node dissection for lymph node recurrent prostate cancer. Curr Opin Urol. 2019 Nov;29(6):629-635. doi: 10.1097/MOU.0000000000000674. PMID: 31503189. (Ver)

Marra G, Valerio M, Heidegger I, Tsaur I, Mathieu R, Ceci F, Ploussard G, van den Bergh RCN, Kretschmer A, Thibault C, Ost P, Tilki D, Kasivisvanathan V, Moschini M, Sanchez-Salas R, Gontero P, Karnes RJ, Montorsi F, Gandaglia G; EAU-YAU Prostate Cancer Working Party. Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. Eur Urol Oncol. 2020 Sep 12:S2588-9311(20)30129-2. doi: 10.1016/j.euo.2020.08.005. Epub ahead of print. PMID: 32933887. (Ver)

Haxhimolla J, Kua B, Gilbourd D, Haxhimolla H. PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management. Semin Oncol Nurs. 2020 Aug;36(4):151044. doi: 10.1016/j.soncn.2020.151044. Epub 2020 Jul 25. PMID: 32723519. (Ver)

Bhargava P, Ravizzini G, Chapin BF, Kundra V. Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed? AJR Am J Roentgenol. 2020 Jun;214(6):1248-1258. doi: 10.2214/AJR.19.21905. Epub 2020 Mar 4. PMID: 32130049. (Ver)

Drost FH, Osses D, Nieboer D, Bangma CH, Steyerberg EW, Roobol MJ, Schoots IG. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis. Eur Urol. 2020 Jan;77(1):78-94. doi: 10.1016/j.eururo.2019.06.023. Epub 2019 Jul 18. PMID: 31326219. (Ver)

Nuevas herramientas en el tratamiento y diagnóstico en cáncer de próstata: HIFU – Biopsa por fusión

Loy LM, Lim GH, Leow JJ, et al. A systematic review and meta-analysis of magnetic resonance imaging and ultrasound guided fusion biopsy of prostate for cancer detection-Comparing transrectal with transperineal approaches. Urologic Oncology. 2020 Aug;38(8):650-660. DOI: 10.1016/j.urolonc.2020.04.005. (Ver)

Ziglioli F, Baciarello M, Maspero G, Bellini V, Bocchialini T, Cavalieri D, Bignami EG, Maestroni U. Oncologic outcome, side effects and comorbidity of high-intensity focused ultrasound (HIFU) for localized prostate cancer. A review. Ann Med Surg (Lond). 2020 May 30;56:110-115. doi: 10.1016/j.amsu.2020.05.029 (Ver)

Watts KL, Frechette L, Muller B, Ilinksy D, Kovac E, Sankin A, Aboumohamed A. Systematic review and meta-analysis comparing cognitive vs. image-guided fusion prostate biopsy for the detection of prostate cancer. Urol Oncol. 2020 Sep;38(9):734.e19-734.e25. doi: 10.1016/j.urolonc.2020.03.020 (Ver)

Marra G, Valerio M, Emberton M, Heidenreich A, Crook JM, Bossi A, Pisters LL. Salvage Local Treatments After Focal Therapy for Prostate Cancer. Eur Urol Oncol. 2019 Sep;2(5):526-538. doi: 10.1016/j.euo.2019.03.008. (Ver)

Boesen L. Magnetic resonance imaging-transrectal ultrasound image fusion guidance of prostate biopsies: current status, challenges and future perspectives. Scand J Urol. 2019 Apr-Jun;53(2-3):89-96. doi: 10.1080/21681805.2019.1600581. (Ver)

Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023. PMID: 31085757. (Ver)

C. Parker, E. Castro, K. Fizazi, A. Heidenreich, P. Ost, G. Procopio, B. Tombal, S. Gillessen,

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. Volume 31, Issue 9, 2020. Pages 1119-1134.ISSN 0923-7534. (Ver)

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25. PMID: 27568654. (Ver)

Sanda, Martin & Cadeddu, Jeffrey & Kirkby, Erin & Chen, Ronald & Crispino, Tony & Fontanarosa, Joann & Freedland, Stephen & Greene, Kirsten & Klotz, Laurence & Makarov, Danil & Nelson, Joel & Rodrigues, George & Sandler, Howard & Taplin, Mary & Treadwell, Jonathan. (2017). Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline, PART I. The Journal of Urology. 199. 10.1016/j.juro.2017.11.095. (Ver)

Braquiterapia

Zhou X, Jiao D, Dou M, Chen J, Han B, Li Z, Li Y, Liu J, Han X. Brachytherapy Combined With or Without Hormone Therapy for Localized Prostate Cancer: A Meta-Analysis and Systematic Review. Front Oncol. 2020 Feb 19;10:169. doi: 10.3389/fonc.2020.00169. (Ver)

Crook J, Marbán M, Batchelar D. HDR Prostate Brachytherapy. Semin Radiat Oncol. 2020 Jan;30(1):49-60. doi: 10.1016/j.semradonc.2019.08.003. (Ver)

Dess RT, Soni PD, Jackson WC, Berlin A, Cox BW, Jolly S, Efstathiou JA, Feng FY, Kishan AU, Stish BJ, Pisansky TM, Spratt DE. The current state of randomized clinical trial evidence for prostate brachytherapy. Urol Oncol. 2019 Sep;37(9):599-610. doi: 10.1016/j.urolonc.2019.04.009. Epub 2019 May 3. (Ver)

Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023. (Ver)

C. Parker, E. Castro, K. Fizazi, A. Heidenreich, P. Ost, G. Procopio, B. Tombal, S. Gillessen,

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. Volume 31, Issue 9, 2020. Pages 1119-1134.ISSN 0923-7534. (Ver)

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25. PMID: 27568654. (Ver)

Sanda, Martin & Cadeddu, Jeffrey & Kirkby, Erin & Chen, Ronald & Crispino, Tony & Fontanarosa, Joann & Freedland, Stephen & Greene, Kirsten & Klotz, Laurence & Makarov, Danil & Nelson, Joel & Rodrigues, George & Sandler, Howard & Taplin, Mary & Treadwell, Jonathan. (2017). Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline, PART I. The Journal of Urology. 199. 10.1016/j.juro.2017.11.095. (Ver)

Cáncer de testículo

Gerstl B, Bertoldo MJ, Sullivan E, Volckmar X, Kerr A, Wand H, Ives A, Albalawi O, Anazodo A. Fatherhood Following Treatment for Testicular Cancer: A Systematic Review and Meta-Analyses. J Adolesc Young Adult Oncol. 2020 Jun;9(3):341-353. doi: 10.1089/jayao.2019.0164. Epub 2020 Apr 7. PMID: 32255696. (Ver)

Thomas KL, Jeong D, Montilla-Soler J, Feuerlein S. The role of diagnostic imaging in the primary testicular cancer: initial staging, response assessment and surveillance. Transl Androl Urol. 2020 Jan;9(Suppl 1):S3-S13. doi: 10.21037/tau.2019.07.01. PMID: 32055480; PMCID: PMC6995841. (Ver)

Masterson TA, Cary C, Foster RS. Current controversies on the role of lymphadenectomy for testicular cancer for the journal: Urologic Oncology: Seminars and Original Investigations for the special seminars section on the role of lymphadenectomy for urologic cancers. Urol Oncol. 2019 Jan 7:S1078-1439(18)30515-5. doi: 10.1016/j.urolonc.2018.12.021. Epub ahead of print. PMID: 30630731. (Ver)

EAU Guidelines. Testicular Cancer. (Ver)

Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, Gilligan T, Karam JA, Leibovich B, Liauw SL, Masterson TA, Meeks JJ, Pierorazio PM, Sharma R, Sheinfeld J. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol. 2019 Aug;202(2):272-281. doi: 10.1097/JU.0000000000000318. Epub 2019 Jul 8. PMID: 31059667. (Ver)

Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Dec;17(12):1529-1554. doi: 10.6004/jnccn.2019.0058. PMID: 31805523. (Ver)

Oldenburg J, Fosså SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, Horwich A, Beyer J, Kataja V; ESMO Guidelines Working Group. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi125-32. doi: 10.1093/annonc/mdt304. PMID: 24078656. (Ver)

Cáncer de pene

Khalil MI, Kamel MH, Dhillon J, et al. What you need to know: updates in penile cancer staging [published online ahead of print, 2020 Jun 22]. World J Urol. 2020;10.1007/s00345-020-03302-z. doi:10.1007/s00345-020-03302-z. (Ver)

Crook J. Organ preserving radiation strategies for penile cancer [published online ahead of print, 2020 Jul 18]. Urol Oncol. 2020;S1078-1439(20)30295-7. doi:10.1016/j.urolonc.2020.06.025. (Ver)

Peyraud F, Allenet C, Gross-Goupil M, et al. Current management and future perspectives of penile cancer: An updated review [published online ahead of print, 2020 Aug 7]. Cancer Treat Rev. 2020;90:102087. doi:10.1016/j.ctrv.2020.102087. (Ver)

Yu YB, Wang YH, Yang XC, et al. The relationship between human papillomavirus and penile cancer over the past decade: a systematic review and meta-analysis. Asian J Androl. 2019;21(4):375-380. doi:10.4103/aja.aja_39_19. (Ver)

Yuan Z, Yang GQ, Ahmed KA, Torres-Roca JF, Spiess PE, Johnstone PA. Radiation therapy in the management of the inguinal region in penile cancer: What’s the evidence? [published online ahead of print, 2020 May 29]. Urol Oncol. 2020;S1078-1439(20)30198-8. doi:10.1016/j.urolonc.2020.05.004. (Ver)

Cassell A, Yunusa B, Manobah B, Wambo D. Management guidelines of penile cancer- a contemporary review of sub-Saharan Africa. Infect Agent Cancer. 2020;15:26. Published 2020 May 1. doi:10.1186/s13027-020-00293-9. (Ver)

Aydin AM, Chahoud J, Adashek JJ, et al. Understanding genomics and the immune environment of penile cancer to improve therapy [published online ahead of print, 2020 Aug 18]. Nat Rev Urol. 2020;10.1038/s41585-020-0359-z. doi:10.1038/s41585-020-0359-z. (Ver)

Tratamiento Sistémico en Cáncer Urológico

Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. Eur Urol. 2020 Aug 12:S0302-2838(20)30532-7. doi: 10.1016/j.eururo.2020.07.003. Epub ahead of print. PMID: 32798146. (Ver)

Perera M, Roberts MJ, Klotz L, Higano CS, Papa N, Sengupta S, Bolton D, Lawrentschuk N. Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer. Nat Rev Urol. 2020 Aug;17(8):469-481. doi: 10.1038/s41585-020-0335-7. Epub 2020 Jun 30. PMID: 32606361. (Ver)

Kumar J, Jazayeri SB, Gautam S, Norez D, Alam MU, Tanneru K, Bazargani S, Costa J, Bandyk M, Ganapathi HP, Koochekpour S, Balaji KC. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis. Urol Oncol. 2020 Nov;38(11):826-834. doi: 10.1016/j.urolonc.2020.03.022. Epub 2020 Jun 28. PMID: 32605736. (Ver)

Daneshmand S, Nazemi A. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. Eur Urol Focus. 2020 Jul 15;6(4):639-641. doi: 10.1016/j.euf.2020.04.011. Epub 2020 May 22. PMID: 32451316. (Ver)

Adashek JJ, Reed JP, Tandon A, Freedland SJ, Posadas E, Bhowmick N, Chung LW, Freeman M, Figlin RA, Gong J. Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment? Clin Genitourin Cancer. 2020 May 11:S1558-7673(20)30101-4. doi: 10.1016/j.clgc.2020.05.003. Epub ahead of print. PMID: 32631766. (Ver)

Pereira-Salgado A, Kwan EM, Tran B, Gibbs P, De Bono J, IJzerman M. Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in? Eur Urol Focus. 2020 Apr 6:S2405-4569(20)30074-2. doi: 10.1016/j.euf.2020.03.003. Epub ahead of print. PMID: 32273196. (Ver)

Shore ND, Antonarakis ES, Cookson MS, Crawford ED, Morgans AK, Albala DM, Hafron J, Harris RG, Saltzstein D, Brown GA, Henderson J, Lowentritt B, Spier JM, Concepcion R. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. Prostate. 2020 May;80(6):527-544. doi: 10.1002/pros.23967. Epub 2020 Mar 4. PMID: 32130741; PMCID: PMC7154535. (Ver)

Buti S, Petrelli F, Ghidini A, Vavassori I, Maestroni U, Bersanelli M. Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis. Clin Transl Oncol. 2020 Sep;22(9):1657-1663. doi: 10.1007/s12094-020-02292-z. Epub 2020 Jan 19. PMID: 31956940. (Ver)

Eulitt PJ, Bjurlin MA, Milowsky MI. Perioperative systemic therapy for bladder cancer. Curr Opin Urol. 2019 May;29(3):220-226. doi: 10.1097/MOU.0000000000000600. PMID: 30855376. (Ver)

Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, Karam JA, Mason RJ, Powles T, Bex A. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol. 2019 Jan;75(1):111-128. doi: 10.1016/j.eururo.2018.09.016. Epub 2018 Oct 25. PMID: 30467042. (Ver)

Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023. PMID: 31085757. (Ver)

Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, Tombal B, Gillessen S; ESMO Guidelines Committee. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Sep;31(9):1119-1134. doi: 10.1016/j.annonc.2020.06.011. Epub 2020 Jun 25. PMID: 32593798. (Ver)

EAU Guidelines. Prostate Cancer. (Ver)

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Mar;18(3):329-354. doi: 10.6004/jnccn.2020.0011. PMID: 32135513. (Ver)

EAU Guidelines. Muscle-invasive and Metastatic Bladder Cancer. (Ver)

Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol. 2017 Sep;198(3):552-559. doi: 10.1016/j.juro.2017.04.086. Epub 2017 Apr 26. Erratum in: J Urol. 2017 Nov;198(5):1175. PMID: 28456635; PMCID: PMC5626446. (Ver)

Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A; ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25 Suppl 3:iii40-8. doi: 10.1093/annonc/mdu223. Epub 2014 Aug 5. PMID: 25096609. (Ver)

EAU Guidelines. Testicular Cancer. (Ver)

Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, Gilligan T, Karam JA, Leibovich B, Liauw SL, Masterson TA, Meeks JJ, Pierorazio PM, Sharma R, Sheinfeld J. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol. 2019 Aug;202(2):272-281. doi: 10.1097/JU.0000000000000318. Epub 2019 Jul 8. PMID: 31059667. (Ver)

Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Dec;17(12):1529-1554. doi: 10.6004/jnccn.2019.0058. PMID: 31805523. (Ver)

Oldenburg J, Fosså SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, Horwich A, Beyer J, Kataja V; ESMO Guidelines Working Group. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi125-32. doi: 10.1093/annonc/mdt304. PMID: 24078656. (Ver)

Van Poppel H, Watkin NA, Osanto S, Moonen L, Horwich A, Kataja V; ESMO Guidelines Working Group. Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi115-24. doi: 10.1093/annonc/mdt286. Epub 2013 Aug 23. PMID: 23975666. (Ver)

EAU Guidelines. Penile Cancer. (Ver)

EAU Guidelines. Renal Cell Carcinoma. (Ver)

Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, Agarwal N, Bhayani S, Choueiri TK, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA; CGC, Hammond LJ, Zuccarino-Catania G. NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. J Natl Compr Canc Netw. 2019 Nov 1;17(11):1278-1285. doi: 10.6004/jnccn.2019.0054. PMID: 31693980. (Ver)

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S, Horwich A; ESMO Guidelines Committee. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 May 1;30(5):706-720. doi: 10.1093/annonc/mdz056. PMID: 30788497. (Ver)

EAU Guidelines. Upper Urinary Tract Urothelial Cell Carcinoma. (Ver)

EAU Guidelines. Primary Urethral Carcinoma. (Ver)

Radioterapia en urología oncológica

Yuan Z, Yang GQ, Ahmed KA, Torres-Roca JF, Spiess PE, Johnstone PA. Radiation therapy in the management of the inguinal region in penile cancer: What’s the evidence? Urol Oncol. 2020 May 29:S1078-1439(20)30198-8. doi: 10.1016/j.urolonc.2020.05.004. Epub ahead of print. PMID: 32482510. (Ver)

Lehrer EJ, Kishan AU, Yu JB, Trifiletti DM, Showalter TN, Ellis R, Zaorsky NG. Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. Radiother Oncol. 2020 Jul;148:235-242. doi: 10.1016/j.radonc.2020.04.037. Epub 2020 Apr 28. PMID: 32505965. (Ver)

Ali A, Parker CC, Clarke NW. Prostate radiotherapy in newly diagnosed metastatic prostate cancer. Curr Opin Urol. 2019 Nov;29(6):620-628. doi: 10.1097/MOU.0000000000000675. PMID: 31584887. (Ver)

Tharmalingam H, Choudhury A, Van Herk M, McWilliam A, Hoskin PJ. New approaches for effective and safe pelvic radiotherapy in high-risk prostate cancer. Nat Rev Urol. 2019 Sep;16(9):523-538. doi: 10.1038/s41585-019-0213-3. Epub 2019 Jul 25. PMID: 31346291. (Ver)

Wettstein MS, Rooprai JK, Pazhepurackel C, Wallis CJD, Klaassen Z, Uleryk EM, Hermanns T, Fleshner NE, Zlotta AR, Kulkarni GS. Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions? PLoS One. 2019 Apr 29;14(4):e0216255. doi: 10.1371/journal.pone.0216255. PMID: 31034504; PMCID: PMC6488073. (Ver)

Daly T. Evolution of definitive external beam radiation therapy in the treatment of prostate cancer. World J Urol. 2020 Mar;38(3):565-591. doi: 10.1007/s00345-019-02661-6. Epub 2019 Mar 8. PMID: 30850855. (Ver)

Korzeniowski MA, Crook JM. Contemporary role of radiotherapy in the management of penile cancer. Transl Androl Urol. 2017 Oct;6(5):855-867. doi: 10.21037/tau.2017.07.02. PMID: 29184783; PMCID: PMC5673811. (Ver)

Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023. PMID: 31085757. (Ver)

Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, Tombal B, Gillessen S; ESMO Guidelines Committee. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Sep;31(9):1119-1134. doi: 10.1016/j.annonc.2020.06.011. Epub 2020 Jun 25. PMID: 32593798. (Ver)

EAU Guidelines. Prostate Cancer. (Ver)

Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. J Urol. 2018 Mar;199(3):683-690. doi: 10.1016/j.juro.2017.11.095. Epub 2017 Dec 15. PMID: 29203269. (Ver)

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Mar;18(3):329-354. doi: 10.6004/jnccn.2020.0011. PMID: 32135513.  (Ver)

EAU Guidelines. Muscle-invasive and Metastatic Bladder Cancer. (Ver)

Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol. 2017 Sep;198(3):552-559. doi: 10.1016/j.juro.2017.04.086. Epub 2017 Apr 26. Erratum in: J Urol. 2017 Nov;198(5):1175. PMID: 28456635; PMCID: PMC5626446. (Ver)

Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A; ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25 Suppl 3:iii40-8. doi: 10.1093/annonc/mdu223. Epub 2014 Aug 5. PMID: 25096609. (Ver)

EAU Guidelines. Testicular Cancer. (Ver)

Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, Gilligan T, Karam JA, Leibovich B, Liauw SL, Masterson TA, Meeks JJ, Pierorazio PM, Sharma R, Sheinfeld J. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol. 2019 Aug;202(2):272-281. doi: 10.1097/JU.0000000000000318. Epub 2019 Jul 8. PMID: 31059667. (Ver)

Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Dec;17(12):1529-1554. doi: 10.6004/jnccn.2019.0058. PMID: 31805523. (Ver)

Oldenburg J, Fosså SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, Horwich A, Beyer J, Kataja V; ESMO Guidelines Working Group. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi125-32. doi: 10.1093/annonc/mdt304. PMID: 24078656. (Ver)

Van Poppel H, Watkin NA, Osanto S, Moonen L, Horwich A, Kataja V; ESMO Guidelines Working Group. Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi115-24. doi: 10.1093/annonc/mdt286. Epub 2013 Aug 23. PMID: 23975666. (Ver)

EAU Guidelines. Penile Cancer. (Ver)

Uso de Pet CT en urología

Koschel S, Murphy DG, Hofman MS, Wong LM. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer. Curr Opin Urol. 2019;29(6):569-577. doi:10.1097/MOU.0000000000000677. (Ver)

Xuan D, Wen W, Tian S, Piao M, Xu D, Liu L. Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with renal carcinoma: A protocol for systematic review and meta analysis. Medicine (Baltimore). 2020;99(20):e19988. doi:10.1097/MD.0000000000019988. (Ver)

Dotzauer R, Thomas C, Jäger W. The use of F-FDG PET/CT in testicular cancer. Transl Androl Urol. 2018;7(5):875-878. doi:10.21037/tau.2018.09.08. (Ver)

Ahn T, Roberts MJ, Abduljabar A, et al. A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC). Mol Imaging Biol. 2019;21(5):799-807. doi:10.1007/s11307-018-01307-0. (Ver)

Xuan D, Wen W, Tian S, Piao M, Xu D, Liu L. Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with renal carcinoma: A protocol for systematic review and meta analysis. Medicine (Baltimore). 2020;99(20):e19988. doi:10.1097/MD.0000000000019988. (Ver)

Trauma de Vía Urinaria Superior

Chien LC, Vakil M, Nguyen J, Chahine A, Archer-Arroyo K, Hanna TN, Herr KD. The American Association for the Surgery of Trauma Organ Injury Scale 2018 update for computed tomography-based grading of renal trauma: a primer for the emergency radiologist. Emerg Radiol. 2020 Feb;27(1):63-73. doi: 10.1007/s10140-019-01721-z. Epub 2019 Sep 5. PMID: 31489487. (Ver)

Gild P, Kluth LA, Vetterlein MW, Engel O, Chun FKH, Fisch M. Adult iatrogenic ureteral injury and stricture-incidence and treatment strategies. Asian J Urol. 2018 Apr;5(2):101-106. doi: 10.1016/j.ajur.2018.02.003. Epub 2018 Feb 17. PMID: 29736372; PMCID: PMC5934506. (Ver)

Sujenthiran A, Elshout PJ, Veskimae E, MacLennan S, Yuan Y, Serafetinidis E, Sharma DM, Kitrey ND, Djakovic N, Lumen N, Kuehhas FE, Summerton DJ. Is Nonoperative Management the Best First-line Option for High-grade Renal trauma? A Systematic Review. Eur Urol Focus. 2019 Mar;5(2):290-300. doi: 10.1016/j.euf.2017.04.011. Epub 2017 May 29. PMID: 28753890. (Ver)

EAU Guidelines. Urological Trauma. (Ver)

Morey AF, Broghammer JA, Hollowell CMP, McKibben MJ, Souter L. Urotrauma Guideline 2020: AUA Guideline. J Urol. 2020 Oct 14:101097JU0000000000001408. doi: 10.1097/JU.0000000000001408. Epub ahead of print. PMID: 33053308. (Ver)

Traumatismo de la vía urinaria inferior y genitales externos masculinos

Fouladi DF, Shayesteh S, Fishman EK, Chu LC. Imaging of urinary bladder injury: the role of CT cystography. Emerg Radiol. 2020 Feb;27(1):87-95. doi: 10.1007/s10140-019-01739-3. Epub 2019 Nov 15. PMID: 31729629. (Ver)

Kominsky H, Beebe S, Shah N, Jenkins LC. Surgical reconstruction for penile fracture: a systematic review. Int J Impot Res. 2020 Jan;32(1):75-80. doi: 10.1038/s41443-019-0212-1. Epub 2019 Nov 4. PMID: 31685943. (Ver)

Light A, Gupta T, Dadabhoy M, Daniel A, Nandakumar M, Burrows A, Karthikeyan S. Outcomes Following Primary Realignment Versus Suprapubic Cystostomy with Delayed Urethroplasty for Pelvic Fracture-Associated Posterior Urethral Injury: A Systematic Review with Meta-Analysis. Curr Urol. 2019 Nov;13(3):113-124. doi: 10.1159/000499282. Epub 2019 Nov 13. PMID: 31933589; PMCID: PMC6944891. (Ver)

Mahat Y, Leong JY, Chung PH. A contemporary review of adult bladder trauma. J Inj Violence Res. 2019 Jul;11(2):101-106. doi: 10.5249/jivr.v11i2.1069. Epub 2019 Apr 13. PMID: 30979861; PMCID: PMC6646823. (Ver)

Lucky M, Brown G, Dorkin T, Pearcy R, Shabbir M, Shukla CJ, Rees RW, Summerton DJ, Muneer A; BAUS Section of Andrology and Genitourethral Surgery (AGUS). British Association of Urological Surgeons (BAUS) consensus document for the management of male genital emergencies – testicular trauma. BJU Int. 2018 Jun;121(6):840-844. doi: 10.1111/bju.14163. Epub 2018 Apr 10. PMID: 29635819. (Ver)

EAU Guidelines. Urological Trauma. (Ver)

Morey AF, Broghammer JA, Hollowell CMP, McKibben MJ, Souter L. Urotrauma Guideline 2020: AUA Guideline. J Urol. 2020 Oct 14:101097JU0000000000001408. doi: 10.1097/JU.0000000000001408. Epub ahead of print. PMID: 33053308. (Ver)

Urología pediátrica

Loebenstein M, Thorup J, Cortes D, Clasen-Linde E, Hutson JM, Li R. Cryptorchidism, gonocyte development, and the risks of germ cell malignancy and infertility: A systematic review. J Pediatr Surg. 2020 Jul;55(7):1201-1210. doi: 10.1016/j.jpedsurg.2019.06.023. Epub 2019 Jul 5. PMID: 31327540. (Ver)

Donaire AE, Mendez MD. Hypospadias. 2020 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 29489236. (Ver)

Mehmood KT, Rentea RM. Ambiguous Genitalia And Disorders of Sexual Differentiation. 2020 Apr 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 32491367. (Ver)

García-Acero M, Moreno O, Suárez F, Rojas A. Disorders of Sexual Development: Current Status and Progress in the Diagnostic Approach. Curr Urol. 2020 Jan;13(4):169-178. doi: 10.1159/000499274. Epub 2020 Jan 7. PMID: 31998049; PMCID: PMC6976999. (Ver)

Logsdon N, Sampaio FJB, Favorito LA. The role of intra-abdominal pressure in human testicular migration. Int Braz J Urol. 2020 Aug 6;46. doi: 10.1590/S1677-5538.IBJU.2021.99.03. Epub ahead of print. PMID: 32758302. (Ver)

Pathak P, Ring JD, Delfino KR, Dynda DI, Mathews RI. Complete primary repair of bladder exstrophy: a systematic review. J Pediatr Urol. 2020 Apr;16(2):149-153. doi: 10.1016/j.jpurol.2020.01.004. Epub 2020 Jan 14. PMID: 32144016. (Ver)

Reifsnyder JE, Hanna MK. Advances in bladder substitution and creation of neobladders in children. F1000Res. 2019 Nov 26;8:F1000 Faculty Rev-1992. doi: 10.12688/f1000research.16607.1. PMID: 31824647; PMCID: PMC6880259. (Ver)

Avanoglu A, Tiryaki S. Embryology and Morphological (Mal)Development of UPJ. Front Pediatr. 2020 Apr 7;8:137. doi: 10.3389/fped.2020.00137. PMID: 32318525; PMCID: PMC7154125. (Ver)

Has R, Sarac Sivrikoz T. Prenatal Diagnosis and Findings in Ureteropelvic Junction Type Hydronephrosis. Front Pediatr. 2020 Sep 4;8:492. doi: 10.3389/fped.2020.00492. PMID: 33014923; PMCID: PMC7498649. (Ver)

Bascietto F, Khalil A, Rizzo G, Makatsariya A, Buca D, Silvi C, Ucci M, Liberati M, Familiari A, D’Antonio F. Prenatal imaging features and postnatal outcomes of isolated fetal duplex renal collecting system: A systematic review and meta-analysis. Prenat Diagn. 2020 Mar;40(4):424-431. doi: 10.1002/pd.5622. Epub 2020 Jan 28. PMID: 31834636. (Ver)

Bingham G, Rentea RM. Posterior Urethral Valve. 2020 Aug 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 32809716. (Ver)

Pomajzl AJ, Sankararaman S. Prune Belly Syndrome. 2020 Aug 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 31334968. (Ver)

Gasthuys E, Dossche L, Michelet R, Nørgaard JP, Devreese M, Croubels S, Vermeulen A, Van Bocxlaer J, Walle JV. Pediatric Pharmacology of Desmopressin in Children with Enuresis: A Comprehensive Review. Paediatr Drugs. 2020 Aug;22(4):369-383. doi: 10.1007/s40272-020-00401-7. PMID: 32507959. (Ver)

Nevéus T, Fonseca E, Franco I, Kawauchi A, Kovacevic L, Nieuwhof-Leppink A, Raes A, Tekgül S, Yang SS, Rittig S. Management and treatment of nocturnal enuresis-an updated standardization document from the International Children’s Continence Society. J Pediatr Urol. 2020 Feb;16(1):10-19. doi: 10.1016/j.jpurol.2019.12.020. Epub 2020 Jan 30. PMID: 32278657. (Ver)

Thergaonkar RW, Hari P. Current Management of Urinary Tract Infection and Vesicoureteral Reflux. Indian J Pediatr. 2020 Aug;87(8):625-632. doi: 10.1007/s12098-019-03099-9. Epub 2019 Dec 11. PMID: 31828601. (Ver)

Rhee DS, Rodeberg DA, Baertschiger RM, Aldrink JH, Lautz TB, Grant C, Meyers RL, Tracy ET, Christison-Lagay ER, Glick RD, Mattei P, Dasgupta R; American Pediatric Surgical Association Cancer Committee. Update on pediatric rhabdomyosarcoma: A report from the APSA Cancer Committee. J Pediatr Surg. 2020 Jun 18:S0022-3468(20)30435-8. doi: 10.1016/j.jpedsurg.2020.06.015. Epub ahead of print. PMID: 32674846. (Ver)

Herramientas metodológicas para la formación de especialistas

Rosen GH, Murray KS, Greene KL, Pruthi RS, Richstone L, Mirza M. Effect of COVID-19 on Urology Residency Training: A Nationwide Survey of Program Directors by the Society of Academic Urologists. J Urol. 2020 Nov;204(5):1039-1045. doi: 10.1097/JU.0000000000001155. Epub 2020 May 28. PMID: 32463716. (Ver)

Harris AM, Ziemba J, Bylund J. Implementing a Root Cause Analysis Program to Enhance Patient Safety Education in Urology Residency. Urology. 2020 Apr;138:24-29. doi: 10.1016/j.urology.2019.11.059. Epub 2020 Jan 21. PMID: 31978526. (Ver)

Bortnick E, Stock J, Simma-Chiang V. Mentorship in Urology Residency Programs in the United States. Urology. 2020 Feb;136:58-62. doi: 10.1016/j.urology.2019.09.053. Epub 2019 Nov 15. PMID: 31738942. (Ver)

Okhunov Z, Safiullah S, Patel R, Juncal S, Garland H, Khajeh NR, Martin J, Capretz T, Cottone C, Jordan ML, McDougall E, Clayman RV, Landman J. Evaluation of Urology Residency Training and Perceived Resident Abilities in the United States. J Surg Educ. 2019 Jul-Aug;76(4):936-948. doi: 10.1016/j.jsurg.2019.02.002. Epub 2019 Feb 23. PMID: 30803721. (Ver)